Efficacy of irbesartan in arterial hypertension and metabolic syndrome


The paper gives the data of Russian guidelines for the diagnosis and approaches to treating metabolic syndrome. It considers the choice of antihypertensive drugs in the treatment of hypertensive patients with metabolic syndrome. The benefits of angiotensin II receptor blockers are shown. The results of a number of trials evaluating the efficacy and safety of irbesartan used to manage arterial hypertension in metabolic syndrome are analyzed.

Full Text

Restricted Access

About the authors

O D Ostroumova

Email: ostroumova.olga@mail.ru

A A Zykova

T A Polosova

O V Bondarets


  1. Рекомендации экспертов Всероссийского научного общества кардиологов по диагностике и лечению метаболического синдрома. Второй пересмотр. Кардиоваскулярная терапия и профилактика. 2009; 6 (Прил. 2): 1–29.
  2. Lakka H.M, Laaksonen D.E, Lakka T.A et al. The metabolic syndrome and total and cardiovascular disease mortality in middle - aged men. JAMA 2002; 288: 2709–16.
  3. Howard G, O'Leary D.H, Zaccaro D et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 1996; 93 (10): 1809–17.
  4. Mule G, Nardi E, Cottone S et al. Infl uence of metabolic syndrome on hypertension - related target organ damage. J Intern Med 2005; 257: 503–13.
  5. Schilacci G, Pirro M, Vaudo G et al. Metabolic syndrome is associated with aortic stiffness in untreated essential hypertension. Hypertension 2005; 45: 1978–82.
  6. Cuspidi C, Meani S, Fusi V et al. Prevalence and correlates of left atrial enlargement in essential hypertension: role of ventricular geometry and the metabolic syndrome: the Evaluation of Target Organ Damage in Hypertension study. J Hypertens 2005; 23: 875–82.
  7. Kavamoto R, Tomita H, Oka Y et al. Metabolic syndrome amplifi es the LDL - cholesterol associated increases in carotid atherosclerosis. Intern Med 2005; 44: 1232–8.
  8. Диагностика и лечение артериальной гипертензии. Системные гипертензии. 2010; 3: 5–26.
  9. Клиническая фармакология. Под ред. В.Г.Кукеса. 4 - е изд. М.: ГЭОТАР - Медиа, 2008; с. 392–5.
  10. Dahlof B, Devereux R.B, Kjeldsen S.E et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995–1003.
  11. Julius S, Kjeldsen S.E, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31.
  12. Pfeffer M.A, Swedberg K, Granger C.B et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362 (9386): 759–66.
  13. Neutel J.M, Saunders E, Bakris G.L et al. The efficacy and safety of lowand high - dose fixed combinations of irbe irbesartan/HCTZ in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) 2005; 7: 578–86.
  14. Чазова И.Е., Ратова Л.Г. Комбинированная терапия артериальной гипертонии. М.: Медиа Медика, 2007; с. 56–73.
  15. Sowers J.R, Neutel J.M, Saunders E et al. Behalf of the INCLUSIVE Investigators. Antihypertensive Efficacy of Irbesartan/HCTZ in Men and Women With the Metabolic Syndrome and Type 2 Diabetes. J Clin Hypertens 2006; 8: 470–80.
  16. Parhofer K.G, Münzel F, Krekler M. Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO - IT prospective observational study. Cardiovasc Diabetol 2007; 6: 36.
  17. Kintscher U, Bramlage P, Paar W.D et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol 2007; 6: 12.



Abstract - 22



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies